10 Most Promising Cancer Stocks According to Wall Street Analysts

In this article, we will be taking a look at the 10 Most Promising Cancer Stocks According to Wall Street Analysts.

Regardless of the state of the economy, the pharmaceutical business has continued to be one of the healthcare market’s most robust sectors thanks to the consistent need for medications, vaccinations, and treatments for chronic illnesses. The S&P 500 Pharmaceutical Index has increased by more over 6%, surpassing the just over 1% increase of the overall S&P 500, demonstrating its defensive strength.

One of the healthcare fields that is growing the fastest, oncology, is a major factor in the long-term expansion of the industry. Immunotherapy and targeted therapeutic advancements, along with the rising global cancer incidence, continue to increase demand. Allied Market Research projects that the oncology pharmaceutical market will grow at a compound annual growth rate (CAGR) of 7.2% to reach $335.2 billion by 2032. Thanks to increased screening programs, increased treatment uptake, and long-term maintenance drugs, the US market for breast cancer medicines alone is projected to reach $6.6 billion by 2036 at a 5.6% CAGR.

The healthcare industry continues to profit from its defensive traits in spite of persistent macroeconomic uncertainties. Although investors are still sensitive to changes in Federal Reserve policy, geopolitical developments, and oil prices, Matt Powers of Powers Advisory Group called the market’s comeback to record highs within 15 trading days a “textbook” V-shaped recovery on April 17. A shift away from highly valued large-cap technology equities and toward more diversified portfolios has also been brought about by these worries. Oppenheimer’s John Stoltzfus says this change could help the healthcare industry, while JPMorgan analysts think the industry is stabilizing after a protracted period of underperformance, even if it has lost roughly 4% this year.

At the same time, rising merger and acquisition activity and stronger insider buying are reinforcing confidence in the industry’s outlook. Deloitte’s February 16, 2026, Global Health Care Outlook found that more than 70% of non-US healthcare executives expect higher revenues and profits, highlighting growing optimism for the sector’s long-term growth prospects.

With that said, let’s now take a look at the most promising stocks.

Our Methodology

For our methodology, we screened for cancer stocks with an analyst upside of at least 20%. From this list, we selected the 10 stocks with the most recent news and developments and ranked them in ascending order based on their analyst upside as of June 25.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Here is our list of the 10 most promising cancer stocks according to Wall Street analysts.

10. Caris Life Sciences, Inc. (NASDAQ:CAI)

Price Target Upside: 49.73%

Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the most promising stocks on our list.

TheFly reported on June 1 that Wolfe Research analyst Mike Polark initiated coverage of CAI and lowered the stock’s rating to Peer Perform from Outperform. The analyst began coverage without assigning a price target.

In other news, on June 16, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that its common shares would receive a dual listing on NYSE Texas, effective June 17, 2026. The company will continue trading on Nasdaq while gaining an additional listing under the same CAI ticker, expanding visibility among investors in Texas and across the broader U.S. market. CAI stated that the move reflects its continued development as a public company and highlights its strong connection to Texas, where it maintains its headquarters and employs more than 450 team members. The company emphasized that the listing supports its focus on advancing AI-driven precision medicine and improving patient outcomes through innovative healthcare solutions.

Caris Life Sciences, Inc. (NASDAQ:CAI) is a TechBio and precision medicine company using molecular profiling and AI to advance personalized oncology and chronic disease care.

9. BeOne Medicines AG (NASDAQ:ONC)

Price Target Upside: 50.00%

BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list.

TheFly reported on June 2 that RBC Capital analyst Leonid Timashev increased the firm’s price target on ONC to $436 from $425 while maintaining an Outperform rating on the shares. The update followed the company’s ASCO presentations featuring three oncology programs, including a CDK4 inhibitor for breast cancer, a GPC3-41BB bispecific candidate for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer. RBC Capital noted that these assets demonstrated encouraging potential, with differentiated safety or efficacy profiles that could position them as leading therapies or strong competitors in their respective markets over time.

More recently, on June 11, BeOne Medicines AG (NASDAQ:ONC) presented Phase 3 data from the SEQUOIA trial in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The analysis, including nearly 6.5 years of follow-up, showed sustained clinical benefits with Brukinsa, highlighting its continued role as a leading BTK inhibitor option. Data from older patients aged 80 and above demonstrated that advanced age did not reduce treatment benefits. The findings further supported Brukinsa’s strong efficacy and safety profile, reinforcing its potential position as a foundational therapy in CLL. The dataset will be presented at the 2026 European Hematology Association Congress.

BeOne Medicines AG (NASDAQ:ONC) is a global oncology company developing and commercializing innovative targeted therapies and immuno-oncology treatments to improve access to cancer care worldwide.

8. Zai Lab Limited (NASDAQ:ZLAB)

Price Target Upside: 67.06%

Zai Lab Limited (NASDAQ:ZLAB) is one of the most promising stocks on our list.

TheFly reported on June 16 that ZLAB announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the company’s potential first-in-class DLL3-targeting antibody-drug conjugate (ADC) for pulmonary neuroendocrine carcinomas (NECs). The designation followed a positive recommendation from the EMA’s Committee for Orphan Medicinal Products, recognizing the significant unmet need for new treatment options in this disease area. The decision was supported by early clinical findings in relapsed or refractory extensive-stage small cell lung cancer, suggesting zoci may provide durable responses and potential advantages compared with existing therapies. The designation may also provide regulatory benefits, including development incentives and possible market exclusivity.

Earlier on June 8, Zai Lab Limited (NASDAQ:ZLAB) announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin for injection) for adults with recurrent or metastatic cervical cancer following disease progression after chemotherapy. The approval was supported by results from the global Phase 3 innovaTV 301 trial, which demonstrated an overall survival benefit compared with chemotherapy. Data from the Chinese patient subgroup showed consistent clinical benefit, including a 45% reduction in the risk of death compared with chemotherapy. No new safety concerns were identified, supporting TIVDAK’s potential use in China.

Zai Lab Limited (NASDAQ:ZLAB) is a global biopharmaceutical company developing and commercializing innovative therapies in oncology, immunology, neuroscience, and infectious diseases across major global markets.

7. Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price Target Upside: 71.30%

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list.

TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical milestones, particularly the expected three-month complete response data from the SURF302 study in induction-refractory non-muscle invasive bladder cancer, anticipated in August 2026. Following discussions with company management, Oppenheimer expressed increased confidence in TYRA’s outlook. The firm also noted the company’s strong cash position of $383.5 million, expected to support operations into the second half of 2028, while viewing its oral treatment approach as a potential advantage in a disease area marked by repeated procedures and recurrence challenges.

Earlier on May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) released its first quarter 2026 financial results, reporting increased investment in clinical development programs. Research and development expenses reached $33.5 million for the quarter ended March 31, 2026, compared with $25.0 million in the prior-year period, mainly due to ongoing dabogratinib activities, including the BEACH301 and SURF302 trials and preparations for SURF303. General and administrative expenses rose to $8.5 million from $6.9 million, driven by higher personnel-related costs. The company reported a first-quarter net loss of $39.3 million, compared with a net loss of $28.1 million during the same period in 2025.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology to treat cancer and genetically defined diseases.

6. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Price Target Upside: 86.77%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list.

TheFly reported on June 12 that Guggenheim analyst Brad Canino reduced the price target for SNDX to $31 from $34 while maintaining a Buy rating on the shares. The updated outlook reflected revisions to the firm’s acute myeloid leukemia market assumptions following new insights on revumenib’s post-transplant maintenance duration from recent medical conference updates. The analyst also considered recent commercial updates from Syndax and Kura Oncology when adjusting the valuation.

Moreover, on June 11, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced the publication of clinical results from the Phase 1/2 SAVE trial evaluating an oral combination regimen of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia with NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. The data were published in the Journal of Clinical Oncology and presented at the 2026 European Hematology Association Congress. The study enrolled 42 patients, including adolescents, and showed an overall response rate of 88% with a 71% composite complete remission rate. The regimen demonstrated activity across genetic subgroups, including patients previously treated with venetoclax, while maintaining a generally manageable safety profile.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company developing innovative therapies for cancer and immune-mediated diseases, with a focus on hematologic malignancies.

5. Janux Therapeutics, Inc. (NASDAQ:JANX)

Price Target Upside: 98.90%

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the most promising stocks on our list.

TheFly reported on June 25 that Truist Securities initiated coverage of JANX with a Buy recommendation and a $26 price target, revised lower from $80. The firm highlighted the need for additional improvements in the tolerability and durability profile of JANX007 while viewing the program as important validation for Janux’s TRACTr platform. Truist also identified potential growth opportunities from additional pipeline candidates, including JANX014, JANX013, and JANX011, which broaden the platform’s applications across oncology and autoimmune conditions.

Earlier on June 23, Janux Therapeutics, Inc. (NASDAQ:JANX) disclosed through an SEC filing that William Go, M.D., Ph.D., had stepped down from his role as Chief Medical Officer. The company stated that his departure was classified as a termination without “Cause” under its Change in Control and Severance Benefit Plan. JANX has started the search process for a replacement, while members of its current clinical leadership team will temporarily oversee responsibilities previously managed by Dr. Go. The company emphasized that the transition does not impact its development strategy, regulatory objectives, or previously announced clinical timelines. JANX also noted that Dr. Go’s departure was not related to any operational, policy, or practice disagreements with the company.

Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies designed to target cancer cells while reducing systemic toxicity.

4. Silence Therapeutics plc (NASDAQ:SLN)

Price Target Upside: 150.00%

Silence Therapeutics plc (NASDAQ:SLN) is one of the most promising stocks on our list.

TheFly reported on June 24 that Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of SLN with an Overweight rating and no price target. The firm highlighted Silence as a clinical-stage biotechnology company developing siRNA-based therapies targeting hematologic, cardiometabolic, and rare diseases. Cantor identified divesiran as a key catalyst, with Phase 2 polycythemia vera data expected in August. The firm expressed confidence in the upcoming results, expecting Divesiran to potentially demonstrate strong efficacy with dosing advantages. Cantor views Silence as undervalued at its current market capitalization of approximately $300 million, with its valuation analysis suggesting more than 160% potential upside and an attractive risk-reward profile ahead of the clinical update.

On June 11, Silence Therapeutics plc (NASDAQ:SLN) presented follow-up and quality-of-life findings from the Phase 1 SANRECO study evaluating divesiran, an siRNA therapy targeting TMPRSS6, in 21 patients with polycythemia vera who required phlebotomy. Data presented at the EHA 2026 Annual Congress showed continued reductions in phlebotomy needs, improved disease-related symptoms, and better quality-of-life measures. During treatment, patients required only 5 phlebotomies compared with 80 in the six months before enrollment, with reduced treatment needs continuing after the final dose. Divesiran was generally well tolerated, supporting further evaluation in the ongoing Phase 2 SANRECO study, which is expected to provide topline results in August 2026.

Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing siRNA-based precision medicines to silence disease-causing genes across hematology, cardiovascular, and rare diseases.

3. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT)

Price Target Upside: 199.09%

BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is one of the most promising stocks on our list.

TheFly reported on June 22 that Oppenheimer initiated coverage of BBOT with an Outperform rating and a $22 price target. The firm highlighted the company’s differentiated oncology pipeline focused on multiple RAS-targeted programs, led by BBO-8520, which is viewed as a potential leading KRAS G12C therapy based on encouraging response data and liver safety results in non-small cell lung cancer. Oppenheimer also noted early potential from additional programs, including BBO-10203 and BBO-11818. With approximately $389 million in cash expected to support operations through 2028, the firm stated that financing concerns are not the main risk factor.

Separately, on May 12, BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) released its first-quarter 2026 financial results alongside a business update highlighting continued pipeline advancement. The company ended the quarter with $388.9 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2028. Research and development spending increased to $39.8 million from $20.6 million a year earlier, driven by clinical and manufacturing activities for BBO-8520, BBO-11818, and BBO-10203. General and administrative expenses rose to $6.4 million from $2.5 million, while quarterly net loss widened to $42.1 million compared with $22.1 million in the prior-year period.

BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting RAS, PI3Kα, and other cancer-driving mutations.

2. Cardiff Oncology, Inc. (NASDAQ:CRDF)

Price Target Upside: 395.87%

Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list.

TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while reaffirming a Buy rating. The revised target reflected uncertainty surrounding an ongoing licensing dispute with Nerviano Medical Sciences involving ownership rights to onvansertib. Despite the legal overhang, the firm believes both companies have strong incentives to resolve the issue in the near future. Lucid Capital also indicated that investor attention could shift back to Cardiff’s clinical progress, with future onvansertib data potentially catalyzing a recovery in the company’s share price.

In addition to that, on June 2, Cardiff Oncology, Inc. (NASDAQ:CRDF) reported data from the Phase 2 CRDF-004 trial evaluating onvansertib with standard chemotherapy in first-line RAS-mutated metastatic colorectal cancer. The 30 mg onvansertib plus FOLFIRI/bevacizumab regimen, selected for Phase 3 development, delivered stronger tumor responses and longer progression-free survival than standard treatment without increasing safety concerns. The combination achieved a 72.2% confirmed objective response rate versus 42.1% for standard therapy alone. Following discussions with the FDA, the company finalized the design of its registrational Phase 3 study, which will evaluate the same regimen as first-line treatment for patients with RAS-mutated metastatic colorectal cancer.

Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company developing precision cancer therapies, led by onvansertib, a PLK1 inhibitor designed to overcome treatment resistance.

1. Heron Therapeutics, Inc. (NASDAQ:HRTX)

Price Target Upside: 631.71%

Heron Therapeutics, Inc. (NASDAQ:HRTX) is one of the most promising stocks on our list.

TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S. District Court for the District of Delaware ruled against the company in its Cinvanti patent litigation. Although the decision was viewed as a setback for HRTX’s intellectual property protections, the firm noted that the company intends to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit, citing confidence in the strength of its legal arguments and the potential for the decision to be overturned.

The revised price target followed HRTX’s June 2 announcement that the Delaware court had invalidated two patents covering its Cinvanti injectable emulsion in litigation involving Azurity Pharmaceuticals and Slayback Pharma. The company emphasized that the ruling does not affect previously executed settlement agreements related to either Cinvanti or Aponvie injectable emulsion. Heron also reaffirmed its plan to challenge the decision before the Federal Circuit, which has jurisdiction over patent appeals, underscoring its commitment to defending its intellectual property despite the unfavorable district court ruling.

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a commercial-stage biotechnology company developing innovative therapies for acute care and oncology using proprietary drug delivery technologies.

READ NEXT: 10 Best Future Stocks to Buy and Hold for 10 Years and 10 Most Promising Long-Term Stocks to Buy According to Analysts.

Disclosure: None. None. Follow Insider Monkey on Google News.